Mumps vaccine effectiveness and risk factors for disease in households during an outbreak in New York City

Vaccine

Volumn 32, Issue 3, 2014, Pages 369-374

  Livingston, Kara A ^a   Rosen, Jennifer B ^b   Zucker, Jane R ^b,c   Zimmerman, Christopher M ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NEW YORK CITY DEPARTMENT OF HEALTH AND MENTAL HYGIENE   (United States)

^c NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

Households; Mumps; Outbreaks; Risk factors; Vaccine effectiveness

Indexed keywords

MEASLES MUMPS RUBELLA VACCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; EPIDEMIC; FEMALE; FOLLOW UP; GROUPS BY AGE; HEALTH SURVEY; HOUSEHOLD; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUMPS; PRIORITY JOURNAL; RISK FACTOR; SELF REPORT; TELEPHONE INTERVIEW; UNITED STATES; VACCINATION; VERY ELDERLY; YOUNG ADULT;

HOUSEHOLDS; MUMPS; OUTBREAKS; RISK FACTORS; VACCINE EFFECTIVENESS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; DISEASE OUTBREAKS; FAMILY CHARACTERISTICS; FAMILY HEALTH; FEMALE; HUMANS; INFANT; MALE; MEASLES-MUMPS-RUBELLA VACCINE; MIDDLE AGED; MUMPS; NEW YORK CITY; RISK FACTORS; YOUNG ADULT;

EID: 84891029054     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.11.021     Document Type: Article

References (40)

1. Centers for Disease Control and Prevention Manual for the surveillance of vaccine-preventable diseases 2008, Centers for Disease Control and Prevention, Atlanta, GA.
2. Centers for Disease Control and Prevention Mumps Epidemic - Iowa, 2006. MMWR Morb Mortal Wkly Rep 2006, 55:1-3.
3. Hviid A., Rubin S., Muhlemann K. Mumps. Lancet 2008, 371:932-944.
4. Centers for Disease Control and Prevention Current trends mumps - United States, 1985-1988. MMWR Morb Mortal Wkly Rep 1989, 38:101-105.
5. Centers for Disease Control and Prevention Achievements in public health, 1900-1999: impact of vaccines universally recommended for children - United States, 1990-1998. MMWR Morb Mortal Wkly Rep 1999, 48:243-248.
6. Dayan G.H., Quinlisk M.P., Parker A.A., Barskey A.E., Harris M.L., Schwartz J.M.H., et al. Recent resurgence of mumps in the United States. N Engl J Med 2008, 358:1580-1589.
7. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2013, 62(4):1-34.
8. Barskey A.E., Glasser J.W., LeBaron C.W. Mumps resurgences in the United States: a historical perspective on unexpected elements. Vaccine 2009, 27:6186-6195.
9. Cardeñosa N., Domínguez A., Camps N., Martínez A., Torner N., Navas E., et al. Non-preventable mumps outbreaks in schoolchildren in Catalonia. Scand J Infect Dis 2006, 38:671-674.
10. Castilla J., Cenoz M.G., Arriazu M., Fernández-Alonso M., Martínez-Artola V., Etxeberria J., et al. Effectiveness of Jeryl Lynn-containing vaccine in Spanish children. Vaccine 2009, 27:2089-2093.
11. Quinlisk P.M. Mumps control today. J Infect Dis 2010, 202:655-656.
12. Levine H., Ankol O.E., Rozhavski V., Davidovitch N., Aboudy Y., Zarka S., et al. Sub-optimal prevalence of mumps antibodies in a population based study of young adults in Israel after 20 years of two dose universal vaccination policy. Vaccine 2011, 29:2785-2790.
13. Cohen C., White J.M., Savage E.J., Glynn J.R., Choi Y., Andrews N., et al. Vaccine effectiveness estimates, 2004-2005 mumps outbreak, England. Emerg Infect Dis 2007, 13:12-17.
14. Centers for Disease Control and Prevention Mumps outbreak - New York, New Jersey, Quebec, 2009. MMWR Morb Mortal Wkly Rep 2009, 58:1-5.
15. Barskey A.E., Schulte C., Rosen J.B., Handschur E.F., Rausch-Phung E., Doll M.K., et al. Mumps outbreak in Orthodox Jewish communities in the United States. N Engl J Med 2012, 367(18):1704-1713.
16. Council for State and Territorial Epidemiologists Revision of the surveillance case definition for mumps. Position Statement 2007 2013, Available at: http://www.cste.org/dnn/AnnualConference/PositionStatements/tabid/191/Default.aspx [accessed 04.10.12].
17. Nguyen T.Q., Thorpe L., Makki H.A., Mostashari F. Benefits and barriers to electronic laboratory results reporting for notifiable diseases: the New York City Department of Health and Mental Hygiene experience. Am J Public Health 2007, 97(S1):S142-S145.
18. Metroka A.E., Hansen M.A., Papadouka V., Zucker J.R. Using an immunization information system to improve accountability for vaccines distributed through the vaccines for children program in New York City, 2005-2008. J Public Health Manag 2009, 15:E13-E21.
19. New York City Department of Health and Mental Hygiene. Immunization Information System Annual Report 2012 2013, Program Operations Branch, Immunization Services Division, Centers for Disease Control and Prevention, Atlanta, GA.
20. New York City Department of Health and Mental Hygiene. Immunization Information System Annual Report 2009 2010, Program Operations Branch, Immunization Services Division, Centers for Disease Control and Prevention, Atlanta, GA.
21. Orenstein W.A., Bernier R.H., Dondero T.J., Hinman A.R., Marks J.S., Bart K.J., et al. Field evaluation of vaccine efficacy. Bull World Health Organ 1985, 63:1055-1068.
22. Harris R.W., Turnbull C.D., Isacson P., Karzon D.T., Winkelstein W. Mumps in a northeast metropolitan community. Am J Epidemiol 1968, 88:224-233.
23. Allison P.D. Logistic regression using the SAS system: theory and application 1999, SAS Institute Incorporate, Cary, NC.
24. Hilleman M.R., Buynak E.B., Weibel R.E., Stokes J. Live, attenuated mumps-virus vaccine. N Engl J Med 1968, 278:227-232.
25. Centers for Disease Control and Prevention. Epidemiology and prevention of vaccine-preventable diseases 2009, Public Health Foundation, Washington DC. 11th ed. W. Atkinson, S. Wolfe, J. Hamborsky, L. McIntyre (Eds.).
26. Marin M., Quinlisk P., Shimabukuro T., Sawhney C., Brown C., Lebaron C.W. Mumps vaccination coverage and vaccine effectiveness in a large outbreak among college students - Iowa, 2006. Vaccine 2008, 26:3601-3607.
27. Harling R., White J.M., Ramsay M.E., Macsween K.F., van den Bosch C. The effectiveness of the mumps component of the MMR vaccine: a case control study. Vaccine 2005, 23(31):4070-4074.
28. Schaffzin J.K., Pollock L., Schulte C., Henry K., Dayan G., Blog D., et al. Effectiveness of previous mumps vaccination during a summer camp outbreak. Pediatrics 2007, 120:862-868.
29. Domínguez A., Torner N., Castilla J., Batalla J., Godoy P., Guevara M., et al. Mumps vaccine effectiveness in highly immunized populations. Vaccine 2010, 28:3567-3570.
30. Lopez Hernandez B., Martin Velez R.M., Roman Garcia C., Sanchez Penalver I., Lopez Rosique J.A. An epidemic outbreak of mumps. A study of vaccinal efficacy. Aten Primaria 2000, 25(3):148-152. 27.
31. Cortese M.M., Jordan H.T., Curns A.T., Quinlan P.A., Ens K.A., Denning P.M., et al. Mumps vaccine performance among university students during a mumps outbreak. Clin Infect Dis 2008, 46:1172-1180.
32. Centers for Disease Control and Prevention Statistics and surveillance: 2010 NIS-Teen Vaccination Coverage Table Data 2013, Available at: http://www.cdc.gov/vaccines/stats-surv/nisteen/data/tables_2010.htm [accessed 06.12.11].
33. New York State. Laws of New York. Public Health Law: Article 21, Title 6, Law §2164 2013, Available at: http://public.leginfo.state.ny.us/LAWSSEAF.cgiQUERYTYPE=LAWS+&QUERYDATA=$$PBH2164$$@TXPBH02164+&LIST=LAW+&BROWSER=BROWSER+&TOKEN=04771095+&TARGET=VIEW [accessed 20.12.11].
34. Fine P.M. Community immunity. Vaccines 2004, 1443-1461. Elsevier, Philadelphia, PA. 4th ed.
35. Anderson R.M., May R.M. Vaccination and herd immunity to infectious diseases. Nature 1985, 318:323-329.
36. Briss P.A., Fehrs L.J., Parker R.A., Wright P.F., Sannella E.C., Hutcheson R.H., et al. Sustained transmission of mumps in a highly vaccinated population: assessment of primary vaccine failure and waning vaccine-induced immunity. J Infect Dis 1994, 169:77-82.
37. Nojd J., Tecle T., Samuelsson A., Orvell C. Mumps virus neutralizing antibodies do not protect against reinfection with a heterologous mumps virus genotype. Vaccine 2001, 19:1727-1731.
38. Date A.A., Kyaw M.H., Rue A.M., Klahn J., Obrecht L., Krohn T., et al. Long-term persistence of mumps antibody after receipt of 2 Measles-Mumps-Rubella (MMR) vaccinations and antibody response after a third MMR vaccination among a university population. J Infect Dis 2008, 197:1662-1668.
39. Rubin S.A., Qi L., Audet S.A., Sullivan B., Carbone K.M., Bellini W.J., et al. Antibody induced by immunization with the Jeryl Lynn mumps vaccine strain effectively neutralizes a heterologous wild-type mumps virus associated with a large outbreak. J Infect Dis 2008, 198:508-515.
40. Centers for Disease Control and Prevention Measles prevention: recommendations of the immunization practices advisory committee (ACIP). MMWR Morb Mortal Wkly Rep 1989, 38(S-9):1-18.